Table 2.
Demographics of 94 Patients Stratified by History of Ir AEs
| Characteristic | All (n=94) |
ir AEs(+) (n=63) | ir AEs(−) (n=31) | P value |
|---|---|---|---|---|
| Age | 70 (37–86) | 70 (37–86) | 68 (46–83) | 0.452 |
| Number of doses | 5 (1–31) | 6 (1–31) | 3 (1–15) | 0.001 |
| Sex, n (%) | ||||
| Male | 82 (87.2) | 57 (90.5) | 25 (80.6) | 0.201 |
| Female | 12 (12.8) | 6 (9.5) | 6 (19.4) | |
| Smoking, n (%) | ||||
| Ever | 84 (89.4) | 58 (92.1) | 26 (83.9) | 0.289 |
| Never | 10 (10.6) | 5 (7.9) | 5 (16.1) | |
| ECOG PS, n (%) | ||||
| 0–1 | 83 (88.3) | 60 (95.2) | 23 (74.2) | 0.005 |
| ≧2 | 11 (11.7) | 3 (4.8) | 8 (25.8) | |
| PD-L1 expression, n (%) | ||||
| ≧50% | 71 (75.5) | 54 (85.7) | 17 (54.8) | 0.002 |
| 1–49% | 23 (24.5) | 9 (14.3) | 14 (45.2) | |
| Treatment line, n (%) | ||||
| First line | 40 (42.6) | 30 (47.6) | 10 (32.3) | 0.187 |
| ≧Second line | 54 (57.4) | 33 (52.4) | 21 (67.7) | |
| Histology, n (%) | ||||
| NonSq | 71 (75.6) | 48 (76.2) | 23 (74.2) | 1.00 |
| Sq | 23 (24.4) | 15 (23.8) | 8 (25.8) |
Abbreviations: irAEs, immune-related adverse events; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand 1: Sq, squamous cell carcinoma.